The above analysis justifies the purposefulness of the performed determination of the expression levels of BIRC genes in patients with triple-negative breast cancer and the correlation of the obtained expression values with clinical data due to the heterogeneous expression profile of the genes in question depending on the expression of ER, PR, and HER2 receptors in breast cancer. This evidence concerns the gene PGR and triple-negative breast carcinoma.